文献速递精神分裂症与精神病性障碍心境障碍儿童青少年精神

κ阿片受体拮抗逆转疾病相关多巴胺转运体变异诱导的磷酸化、转运与行为异常

Kappa opioid receptor antagonism restores phosphorylation, trafficking and behavior induced by a disease-associated dopamine transporter variant.
PubMed 文献 · Mol Psychiatry · 2025-05-29

研究利用表达人类DAT Val559变异(见于ADHD、ASD、BPD个体)的临床前小鼠模型,发现KOR激动可增强野生型DAT表面转运及Th53磷酸化,而该效应在Val559突变体中呈组成性激活;KOR拮抗可逆转离体及在体DA释放异常和性别依赖性行为异常。鉴于KOR拮抗剂滥用潜力低,研究支持其作为治疗DA相关脑部疾病的药理策略。

要点

  • KOR激动增强野生型DAT表面转运和Th53磷酸化,Val559突变体组成性表现这些效应。
  • KOR拮抗可逆转DAT Val559离体异常及在体DA释放和性别依赖性行为异常。
  • KOR拮抗剂滥用潜力低,支持其治疗DA相关脑部疾病的转化考虑。

核心结论

  • KOR拮抗可纠正DAT Val559变异诱导的DA释放及行为异常,支持其作为低滥用潜力治疗DA相关脑部疾病的策略。

研究设计与样本

  • 临床前小鼠模型研究,使用表达人类DAT Val559变异(见于ADHD、ASD或BPD个体)的小鼠。

主要发现

  • KOR激动增强野生型DAT表面转运和Th53磷酸化,Val559突变体组成性表现这些效应。
  • KOR拮抗可逆转DAT Val559离体异常及在体DA释放和性别依赖性行为异常。

临床怎么用

  • KOR拮抗剂滥用潜力低,可考虑作为治疗DA相关脑部疾病的药理策略。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Aberrant dopamine (DA) signaling is implicated in schizophrenia, bipolar disorder (BPD), autism spectrum disorder (ASD), substance use disorder, and attention-deficit/hyperactivity disorder (ADHD). Treatment of these disorders remains inadequate, as exemplified by the therapeutic use of d-amphetamine and methylphenidate for the treatment of ADHD, agents with high abuse liability. In search for an improved and non-addictive therapeutic approach for the treatment of DA-linked disorders, we utilized a preclinical mouse model expressing the human DA transporter (DAT) coding variant DAT Val559, previously identified in individuals with ADHD, ASD, or BPD. DAT Val559, like several other disease-associated variants of DAT, exhibits anomalous DA efflux (ADE) that can be blocked by d-amphetamine and methylphenidate. Kappa opioid receptors (KORs) are expressed by DA neurons and modulate DA release and clearance, suggesting that targeting KORs might also provide an alternative approach to normalizing DA-signaling disrupted by perturbed DAT function. Here we demonstrate that KOR stimulation leads to enhanced surface trafficking and phosphorylation of Thr53 in wildtype DAT, effects achieved constitutively by the Val559 mutant. Moreover, these effects can be rescued by KOR antagonism of DAT Val559 in ex vivo preparations. Importantly, KOR antagonism also corrected in vivo DA release as well as sex-dependent behavioral abnormalities observed in DAT Val559 mice. Given their low abuse liability, our studies with a construct valid model of human DA associated disorders reinforce considerations of KOR antagonism as a pharmacological strategy to treat DA associated brain disorders.

来源:Mol Psychiatry,查看原文。版权归原作者所有。

引用

  1. Mayer FP, Stewart A, Varman DR, et al. Kappa opioid receptor antagonism restores phosphorylation, trafficking and behavior induced by a disease-associated dopamine transporter variant. Mol Psychiatry. 2025. PMID: 40442453. doi:10.1038/s41380-025-03055-4

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。